Evidence Table 164. KQ4—Continuous data—Clearance

| **Author Year**  **Study Design** | **Definition of outcome** | **CHD Risk Category** | **CVD drug (dose mg/d)** | **Supplement/ Control** | **N** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***Clearance (V/time)*** |  |  |  |  |  |  |  |  |  |  |
| Jiang 200433  Cross-over | R-Warfarin: CL/F  (mL/min); measured after single dose warfarin following 1 wk pretreatment with ginseng or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Ginseng (3) | 12 | Mean: 119  SD: 20  Lower: 106  Upper:131 | - | GMRdiff:1.10  Lower: 1.01  Upper: 1.20 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean:110  SD: 25  Lower: 94  Upper: 126 | - |
|  | S-Warfarin: CL/F  (mL/min); measured after single dose warfarin following 1 wk pretreatment with ginseng or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Ginseng (3) | 12 | Mean: 220  SD: 29  Lower: 201  Upper:238 | - | GMRdiff:1.12  Lower: 1.03  Upper:1.22 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean:198  SD: 38  Lower: 174  Upper: 223 | - |
| Hajda 201028 | Clearance (CL/F) of statin (L/h) | Low (healthy men) | Simvastatin (20) | Garlic extract (600 mg twice daily) | 10 | Mean: 2146  SD: 1660 | - | - | - | Medium |
| No treatment | 10 | Mean: 2349  SD: 1340 | - | - | - |

| Evidence Table 164. KQ4—Continuous data—Clearance (continued) | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author Year**  **Study Design** | **Definition of outcome** | **CHD Risk Category** | **CVD drug (dose mg/d)** | **Supplement/ Control** | **N** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| Hajda 201028 | Clearance (CL/F) of statin (L/h) (details not reported) | Low (healthy men) | Pravastatin (20) | Garlic extract (600 mg twice daily) | 10 | Mean: 722  SD:440 | - | - | - | Medium |
| No treatment | 10 | Mean: 834  SD: 928 | - | - | - |
| Jiang 200532  Cross-over | R-Warfarin:  CL/F  (mL/min); measured after single dose warfarin following 1 week pretreatment with Ginger, Ginkgo biloba or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Ginger (3.6) | 12 | Mean:131  Lower: 106  Upper: 156 | - | Ginger  GMRdiff:1.02  Lower: 0.95  Upper:1.10  Ginkgo biloba  GMRdiff:1.00  Lower: 0.93  Upper:1.08 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| Ginkgo biloba(12) | 12 | Mean:126  Lower: 111  Upper: 141 | - |
| No treatment | 12 | Mean:127  Lower: 106  Upper: 149 | - |
| S-Warfarin:  CL/F  (mL/min); measured after single-dose warfarin following 1 wk pretreatment with Ginger, Ginkgo biloba or no pretreatment. Subjects followed for 1 wk post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Ginger (3.6) | 12 | Mean:201  Lower: 171  Upper: 231 | - | Ginger  GMRdiff:1.05  Lower: 0.97  Upper:1.13  Ginkgo biloba  GMRdiff:1.05  Lower: 0.98  Upper:1.12 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI |  |
| *Ginkgo biloba* (12) | 12 | Mean:200  Lower: 173  Upper: 227 | - |
| No treatment | 12 | Mean:189  Lower: 167  Upper: 210 |
| Abdul 20101  Cross-over | R-Warfarin:  mL/h; measured after single dose warfarin following 2 wks pretreatment with Echinacea or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | *Echinacea* (5.1; 23 mg total alkamides) | 12 | Mean:186.4  Lower: 140.5  Upper: 232.2 | - | GMRdiff:1.10  Lower: 0.97  Upper:1.14 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean:178.3  Lower: 132.7  Upper: 223.4 | - |
| S-Warfarin:  mL/h; measured after single dose warfarin following 2 wks pretreatment with Echinacea or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | *Echinacea* (5.1; 23 mg total alkamides) | 12 | Mean:289.7  Lower: 218.2  Upper: 361.1 | - | GMRdiff:1.09  Lower: 1.01  Upper:1.18 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean:267.3  Lower198.4  Upper: 336.3 | - |
| Mohammed Abdul 200849  Cross-over | R-Warfarin:  mL/h; measured after single dose warfarin following 2 wks pretreatment with garlic or no pretreatment. Subjects followed for one more week post warfarin dose. | Low (healthy) | Warfarin (25; single dose) | Garlic (4; 7.42 mg allicin) | 12 | Mean: 121  Lower: 112  Upper: 131 | - | GMRdiff: 0.96  Lower: 0.84  Upper:1.11 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 123  Lower: 106  Upper: 140 | - |
| S-Warfarin:  mL/h; measured after single dose warfarin following 2 wks pretreatment with garlic or no pretreatment. Subjects followed for one more week post warfarin dose | Low (healthy) | Warfarin (25; single dose) | Garlic (4; 7.42 mg allicin) | 12 | Mean: 202  Lower: 175  Upper: 229 | - | GMRdiff: 1.05  Lower: 0.94  Upper:1.17 | Upper and lower limits of individual group data = 95% CI; Upper and lower limits of between group difference = 90% CI | Medium |
| No treatment | 12 | Mean: 213  Lower: 193  Upper: 232 | - |
| McKenney 200645  Cross-over | CL/F (L/h) Total body clearance at steady state vs. time curve over the final dosing interval (0-24 h) | Low and/or Moderate | Simvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 21 | Mean: 838  SD: 477 | - | - | - | Medium |
| No treatment | 18 | Mean: 872  SD: 402 | - |
| Tankanow 200365  Cross-over | mL/min; Measured after 10 days digoxin or 21 days digoxin + hawthorn | Low (healthy) | Digoxin (0.25; single dose) | Hawthorn (0.9) | 8 | Mean: 81  SD: 22 | - | - | - | Medium |
| No treatment | 8 | Mean: 74  SD: 10 | - |
| Mauro 200343  Cross-over | Oral clearance (L/h); Measured after single-dose administration of digoxin following 7 days pre-treatment with Ginkgo biloba or no pre-treatment | Low (healthy) | Digoxin (0.5; single dose) | *Ginkgo biloba* (0.24) | 8 | Mean: 26.6  SD: 18.1 | - | - | - | Medium |
| No treatment | 8 | Mean: 31.7  SD: 24.9 | - |
| Gosai 200826  Cross-over | Total body clearance at steady state (L/h); 2 weeks treatment | Low (healthy) | Rovustatin (40) | Omega-3 fatty acids (EPA, DHA or both) (4) | 42 | Mean: 204  SD: 88.5 | - | - | % coefficient of variation:  Omega-3: 43.36  Control: 36.25 | Medium |
| No treatment | 41 | Mean: 208  SD: 75.3 | - |
| Di Spirito 200819  Cross-over | Total body clearance at steady state vs. Time curve over the final dosing interval (0-24 h) | Low (healthy) | Atorvastatin (80) | Omega-3 fatty acids (EPA, DHA or both) (4) | 49 | Mean: 413  SD: 179 | - | - | - | Medium |
| No treatment | 49 | Mean: 423  SD: 183 | - |